PMID- 16012182
OWN - NLM
STAT- MEDLINE
DCOM- 20060127
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 16
IP  - 9
DP  - 2005 Sep
TI  - Retinoid receptors in ovarian cancer: expression and prognosis.
PG  - 1477-87
AB  - BACKGROUND: Ovarian cancer is frequently lethal despite aggressive multimodal 
      therapy, and new therapies are therefore needed. Retinoids are potential 
      candidate drugs: they prevent the development of ovarian carcinoma and enhance 
      the efficacy of cytotoxic drugs in ovarian cancer cells. At present, little is 
      known about the retinoid receptor expression in ovarian cancer. PATIENTS AND 
      METHODS: The retinoid receptors comprise two classes, retinoic acid receptors 
      (RARs) and retinoid X receptors (RXRs), each with three subclasses, alpha, beta 
      and gamma. We investigated the expression of the subtypes RARalpha, RARgamma, 
      RXRalpha and RXRbeta by immunohistochemistry in ovarian cancers of 80 patients, 
      and assessed their prognostic significance. In addition, we quantified the 
      expression of retinoid receptor mRNA using real-time PCR and correlated the 
      results with clinical characteristics. RESULTS: RARalpha and RXRbeta were highly 
      expressed in a majority of ovarian cancers, particularly in advanced stages. High 
      expression of RARalpha was an independent negative prognostic factor of survival 
      in addition to FIGO stage, age and p53 accumulation. The mRNA expression of 
      retinoid receptors did not correlate with clinical properties of the tumors. 
      CONCLUSIONS: Retinoic acid receptors are frequently and strongly expressed in 
      epithelial ovarian cancer and may be indicators of an adverse prognosis. This 
      study provides the molecular basis for the therapeutic use of retinoids in 
      ovarian cancer.
FAU - Kaiser, P C
AU  - Kaiser PC
AD  - University Hospital Berne, Department of Medical Oncology, Bern, Switzerland.
FAU - Korner, M
AU  - Korner M
FAU - Kappeler, A
AU  - Kappeler A
FAU - Aebi, S
AU  - Aebi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050712
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (DNA Primers)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Retinoic Acid)
SB  - IM
MH  - Aged
MH  - Base Sequence
MH  - DNA Primers
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Ovarian Neoplasms/*metabolism/pathology
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Receptors, Retinoic Acid/classification/genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2005/07/14 09:00
MHDA- 2006/01/28 09:00
CRDT- 2005/07/14 09:00
PHST- 2005/07/14 09:00 [pubmed]
PHST- 2006/01/28 09:00 [medline]
PHST- 2005/07/14 09:00 [entrez]
AID - S0923-7534(19)54972-9 [pii]
AID - 10.1093/annonc/mdi265 [doi]
PST - ppublish
SO  - Ann Oncol. 2005 Sep;16(9):1477-87. doi: 10.1093/annonc/mdi265. Epub 2005 Jul 12.